FLAURA study: a new standard of care for patients with EGFR mutated NSCLC

A New Standard of Care: Dr. Ramalingam Discusses LAURA Results, Implications With the Two Onc DocsПодробнее

LAURA trial: a new standard of care in unresectable stage III EGFRm NSCLCПодробнее

Osimertinib for EGFR-mutant lung cancerПодробнее

15 Years of Advances in EGFR Mutant Lung CancerПодробнее

Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLCПодробнее

2023 Best of Lung: Targeted Therapies in Lung CancerПодробнее

EGFR TKI Resistance: Progress and ChallengesПодробнее

Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLCПодробнее

Raffaele Califano, ESMO 2019 - FLAURA study in NSCLCПодробнее

FLAURA final analysis: osimertinib for first-line EGFRm NSCLCПодробнее

Osimertinib suitable for first line EGFRm lung cancerПодробнее

New Standard for Treating Stage 4 EGFR+ NSCLCПодробнее

Targeted treatment with EGFR TKIs: Front line optionsПодробнее

Understanding, preventing, and delaying EGFR resistance in the era of OsimertinibПодробнее

New standard of care for lung cancer patients with EGFR mutationsПодробнее

Osimertinib: A potential new standard of care for advanced EGFR-mutated NSCLC | Suresh RamalingamПодробнее

FLAURA study of osimertinib versus TKI for 1st line NSCLCПодробнее

Gene Targeted Therapy for Non Small Cell Lung CancerПодробнее

NSCLC: Integrating EGFR-Inhibiting Therapies into Clinical Pathways for First-Line TreatmentПодробнее

Case 2: Osimertinib in EGFR-Mutated Lung CancerПодробнее